SENS vs. TXG, TRNS, EYPT, ALNT, CTKB, LAB, AEHR, QSI, MASS, and QTRX
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include 10x Genomics (TXG), Transcat (TRNS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Standard BioTools (LAB), Aehr Test Systems (AEHR), Quantum-Si (QSI), 908 Devices (MASS), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry.
Senseonics vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
10x Genomics received 59 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 50.00% of users gave 10x Genomics an outperform vote while only 17.07% of users gave Senseonics an outperform vote.
In the previous week, 10x Genomics had 6 more articles in the media than Senseonics. MarketBeat recorded 7 mentions for 10x Genomics and 1 mentions for Senseonics. Senseonics' average media sentiment score of 1.75 beat 10x Genomics' score of 0.52 indicating that Senseonics is being referred to more favorably in the news media.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 12.4% of Senseonics shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 4.3% of Senseonics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Senseonics has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Senseonics, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
10x Genomics currently has a consensus price target of $15.81, suggesting a potential upside of 51.85%. Senseonics has a consensus price target of $1.55, suggesting a potential upside of 208.89%. Given Senseonics' stronger consensus rating and higher probable upside, analysts clearly believe Senseonics is more favorable than 10x Genomics.
10x Genomics has a net margin of -29.90% compared to Senseonics' net margin of -362.30%. 10x Genomics' return on equity of -25.40% beat Senseonics' return on equity.
Summary
10x Genomics beats Senseonics on 11 of the 19 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
This page (NYSE:SENS) was last updated on 6/15/2025 by MarketBeat.com Staff
Buy SENS Stock Free SENS Stock Alerts